Jacobs Levy Equity Management, Inc Zentalis Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 700,576 shares of ZNTL stock, worth $931,766. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700,576
Previous 857,582
18.31%
Holding current value
$931,766
Previous $994,000
6.34%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ZNTL
# of Institutions
109Shares Held
58MCall Options Held
0Put Options Held
43.4K-
Matrix Capital Management Company, LP Waltham, MA14MShares$18.6 Million33.01% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.41 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.9MShares$3.86 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.85MShares$3.78 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.33MShares$3.09 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $75.8M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...